Microbiota based personalized nutrition improves hyperglycaemia and hypertension parameters and reduces inflammation: A prospective, open label, controlled, randomized, comparative, proof of concept study

Abstract

Recent studies suggest that gut microbiota composition, abundance and diversity can influence many chronic diseases such as type 2 diabetes. Modulating gut microbiota through targeted nutrition can provide beneficial effects leading to the concept of personalized nutrition for health improvement. In this prospective clinical trial, we evaluated the impact of a microbiome-based targeted personalized diet on hyperglycaemic and hyperlipidaemic individuals. Specifically, BugSpeaks®- a microbiome profile test that profiles microbiota using next generation sequencing and provides personalized nutritional recommendation based on the individual microbiota profile was evaluated. The test arm [microbiome-based nutrition] showed a statistically significant decrease in HbA1c level [from 8.30 ± 1.12 to 6.67 ± 0.89, p<0.001] after 90 days. The test arm, also showed a 5% decline in the systolic pressure whereas the control arm showed a 7% increase. Incidentally, a sub-cohort of the test arm of patients with >130mm Hg systolic pressure showed a statistically significant decrease of systolic pressure by 14%. Interestingly, CRP level was also found to drop by 19.5%. Alpha diversity measures showed a significant increase in Shannon diversity measure [p<0.05], after the microbiome-based personalized dietary intervention. The intervention led to a minimum 2-fold [Log2 fold change] increase in beneficial species likePhascolarctobacterium succinatutens, Bifidobacterium angulatum, Levilactobacillus brevis, and a similar decrease in non-beneficial species likeAlistipes finegoldii, Sutterella faecalis. Overall, the study indicated a net positive impact of the microbiota based personalized dietary regime on the gut microbiome and correlated clinical parameters.

Microbiota based personalized nutrition improves hyperglycaemia and hypertension parameters and reduces inflammation: a prospective, open label, controlled, randomized, comparative, proof of concept study

“…Present clinical trial was conducted to evaluate the safety and impact of BugSpeaks ® microbiome-based personalized dietary regime in hyperglycaemic and hyperlipidaemic individuals, specifically to evaluate the impact of such diet on gut microbiota and other disease related clinical parameters. Please note, that portions of this text were previously published as part of a preprint ( Kallapura et al, 2023 ). The current clinical trial was a randomized, double-blinded, prospective study, initiated with 30 Indian subjects with hyperglycaemia and/or hyperlipidaemia per study design ( Fig.…”

“…This suggests that a personalized diet based on one’s gut microbiome could significantly help in lowering hyperglycaemia and alleviating its negative effects ( Singh et al, 2017 ; Ben-Yacov et al, 2023 ). A study conducted by the Mayo Clinic Centre for individualized medicine found that a personalized diet based on one’s microbiome (along with genetics, age, and activity level) is a far better way to control one’s blood glucose than cutting carbohydrates and calories ( Mendes-Soares et al, 2019 ; Stanimirovic et al, 2022 ; Kallapura et al, 2023 ). This approach fits into precision medicine paradigm by considering different diet patterns and adopting the best one based on individual microbiota composition to achieve significant adiposity reduction and improve metabolic status ( De Coster et al, 2018 ; Nurk et al, 2022 ; Langmead & Salzberg, 2012 ).…”